References

1. Ottesen EA: The global programme to eliminate lymphatic filariasis.

   Trop Med Int Health 2000, 5:591-594. PubMed Abstract | Publisher Full Text

2. Das PK, Pani SP, Krishnamoorthy K: Prospects of elimination of lymphatic filariasis in India.

   ICMR Bulletin 2002, 32:41-54.

3. Michael E, Bundy DAP, Grenfell BT: Re-assessing the global prevalence and distribution of lymphatic filariasis.

   Parasitology 1996, 112:409-428. PubMed Abstract

4. Das PK, Pani SP: Towards elimination of lymphatic filariasis in India: Problems, challenges, opportunities and new initiatives.

   J Int Med Sci Acad 2000, 13:18-26.

5. Ottesen EA, Duke BOL, Karam M, Behbehani K: Strategies and tools for the control /elimination of lymphatic filariasis.

   Bull World Health Organ 1997, 75:491-503. PubMed Abstract

6. Sabesan S, Palaniyandi M, Das PK, Michael E: Mapping of lymphatic filariasis in India.

   Ann Trop Med Parasitol 2000, 94:591-606. PubMed Abstract

7. Pani SP, Yuvraj J, Vanamail P, Dhanda V, Michael E, Grenfell BT, Bundy DAP: Episodic adenolymphangitis and lymphoedema in patients with bancroftian filariasis.

   Trans R Soc Trop Med Hyg 1995, 89:72-74. PubMed Abstract

8. Ramaiah KD, Vijay Kumar KN, Ramu K, Pani SP, Das PK: Functional impairment caused by lymphatic filariasis in rural areas of south India.

   Trop Med Int Health 1997, 2:832-838. PubMed Abstract

9. World Health Organization: The state of world health.

   World Health Report-Bridging the gaps (WHO, Geneva) 1995, 1:42.

10. Ramaiah KD, Das PK, Michael E, Guyatt H: The Economic Burden of Lymphatic Filariasis in India.

    Parasitology Today 2000, 16:251-253. PubMed Abstract | Publisher Full Text

11. Centre for Disease Control (CDC): Recommendations of the International Task Force for Disease Eradication.

    Morbidity and Mortality Weekly Report 1993, 42:1-38. PubMed Abstract

12. World Health Organization: Resolution of the Executive Board of the WHO: Elimination of Lymphatic Filariasis as a Public Health Problem.

    Fiftieth World Health Assembly, Geneva WHA 50.29:

    13 May 1997

13. Dreyer G, Addiss D, Bettinger J, Dreyer P, Noroes J, Rio F: Introduction.

    Lymphoedema Staff Manual: Treatment and Prevention of problems Associated with Lymphatic Filariasis (WHO, Geneva) 2000, v-vii.

14. Ottesen EA, Ismail MM, Horton J: The role of Albendazole in programmes to eliminate lymphatic filariasis.

    Parasitology Today 1999, 15:382-386. PubMed Abstract | Publisher Full Text

15. Pani SP, Subramanyam Reddy G, Das LK, Vanamail P, Hoti SL, Ramesh J, Das PK: Tolerability and efficacy of single dose albendazole, diethylcarbamazine (DEC) or co-administration of albendazole with DEC in the clearance of Wuchereria bancrofti in asymptomatic microfilaraemic volunteers in Pondicherry, South India: a hospital-based study. [http://www.Filariajournal.com/content/1/1/1]

    Filaria Journal 2002., 1:

16. Dreyer G, Noroes J, Figueredo-Silva J, Piessens WF: Pathogenesis of Lymphatic Disease in Bancroftian Filariasis: A Clinical Perspective.

    Parasitology Today 2000, 16:544-548. PubMed Abstract | Publisher Full Text

17. Das PK, Pani SP: Towards elimination of lymphatic filariasis in India, problems, challenges, opportunities and new initiatives.

    J Int Med Sci Acad 2000, 13:18-26.

18. BIO-GARD: Drug acting on alimentary system.

    Current Index of Medical Specialities 1998, 21:56-95.

19. Pecking AP, Fevier B, Wargon C, Pillion G: Efficacy of Daflon 500 mg in the treatment of lymphedema (secondary to conventional therapy of breast cancer).

    Angiology 1997, 48:93-98. PubMed Abstract

20. Le Deyehat C, Khodabandehlou T, Vimeux M, Kempf C: Evaluation of haemorrhagical and microcirculatory disturbances in chronic venous insufficiency: activity of Daflon 500 mg.

    Int J Microcirc Clin Exp 1997, 17(Suppl 1):27-33. PubMed Abstract

21. Cospite M: Double-blind placebo-controlled evaluation of clinical activity and safety of Daflon 500 mg in the treatment of acute hemorrhoids.

    Angiology 1994, 45:566-573. PubMed Abstract

22. Meyer OC: Safety and security of Daflon 500 mg in venous insufficiency and in hemorrhoidal disease.

    Angiology 1994, 45:579-584. PubMed Abstract

23. Colgan MP, Moore DJ, Shanik DG: New approaches in the medical management of venous ulceration.

    Angiology 1993, 44:138-142. PubMed Abstract

24. Guilhou JJ, Debure O, Marzin L, Ouvry P, Zuccarelli F, Debure C, Van Landuyt H, Gillet-Terver MN, Guillot B, Levesque H, Mignot J, Pillion G, Fevrier F, Dubeaux D: Efficacy of Daflon 500 mg in venous leg ulcer healing: a double-blind, randomized, controlled versus placebo trial in 107 patients.

    Angiology 1997, 48:77-85. PubMed Abstract

25. Struckmann JR: Clinical efficacy of micronized flavonoid fraction: an overview.

    J Vasc Res 1999, 36(Suppl 1):37-41. PubMed Abstract | Publisher Full Text

26. Pecking AP: Evaluation by lymphoscintigraphy of the effect of a micronized flavonoid fraction (Daflon 500 mg) in the treatment of upper limb lymphedema.

    Int Angiol 1995, 14(Suppl 1):39-43. PubMed Abstract

27. Pani SP, Srividya A, Rajagopalan PK: Clinical manifestations of bancroftian filariasis in relation to microfilaraemic and Diethylcarbamazine therapy.

    The National Medical Journal of India 1991, 4:9-14.

28. Pani SP, Dhanda V: Natural history and dynamics of progression of clinical manifestation of filariasis.

    In: Tropical Disease: Molecular Biology and Control Strategies (Edited by: Kumar S, Sen AK, Dutta GP, Sharma RN). Publication and Information Directorate, CSIR, New-Delhi 1994, 1-8.

29. Pani SP, Lall R: Clinical features, pathogenesis and management of lymphatic filariasis.

    ICMR Bulletin 1998, 28:41-51.

30. Hoti SL, Elango A, Radjame K, Yuvraj J, Pani SP: Utility of filter paper samples in the detection of day blood filarial antigens by Og4C3 ELISA test: sensitivity during different periods of the day.

    The National Medical Journal of India 2002, 15:197-201.

31. World Health Organization: Informal consultation on evaluation of morbidity in lymphatic filariasis.

    WHO/TDR/FIL/MAD/92.3 1992, 1-8.

32. World Medical Association: Declaration of Helsinki – Recommendations guiding physicians in biomedical research involving human subjects. [http://www.who.int/medicines/library/par/ggcp/GCPGuidePharmatrials.pdf]

    In: WHO Technical Report Series, No. 850, Annex 3 1995, 30-33.

33. World Health Organization: Guidelines for good clinical practice (GCP) for trials on pharmaceutical products. [http://www.who.int/medicines/library/par/ggcp/GCPGuidePharmatrials.pdf]

    WHO Technical Report Series, No. 850, Annex 3 1995, 1-35.

34. Indian Council of Medical Research: Statement of general principles on ethical considerations involving human subjects.

    In: Ethical guidelines for biomedical research on human subjects 2000, 1-8.

35. Pani SP, Vanamail P, Yuvraj J: Limb circumference measurement for recording edema volume in patients with filarial lymphedema.

    Lymphology 1995, 28:57-63. PubMed Abstract

36. Ministry of Health and Family Welfare Government of India: National Health Policy. [http://mohfw.nic.in/np2002.htm]

    2002.

37. Binoy C, Govardha Rao V, Ananthakrishnan N, Kate V, Yuvraj J, Pani SP: Omentoplasty in the management of filarial lymphoedema.

    Trans R Soc Trop Med Hyg 1998, 92:317-319. PubMed Abstract

38. Govardhan Rao V, Ananthakrishnan N, Pani SP, Kate V, Yuvraj J, Krishnamoorthy K: Factors influencing response to lymphonodo-venous shunt in filarial lymphoedema.

    The National Medical Journal of India 1999, 12:55-58. PubMed Abstract

39. Foldi E, Foldi M, Clodius L: The lymphoedema Chaos: A Lancet.

    Annals of Plastic Surgery 1989, 22:505-515. PubMed Abstract

40. Zelikovski A, Deutsch A, Reiss R: The sequential pneumatic compression device in surgery for lymphedema in the limbs.

    J Cardiovas Surg (Tarino) 1993, 24:122-126. PubMed Abstract

41. Vector Control Research Centre: Brugian filariasis and its control in Cherthala, Kerala state.

    Annual Report 1994, 14-18.

42. Manjula Y, Kate V, Ananthkrishnan N: Evaluation of sequential intermittent pneumatic compression in filarial lymphoedema.

    The National Medical Journal of India 2002, 15:192-194. PubMed Abstract

43. Pani SP, Yuvraj J, Vijayalakshmi : Medical Management of lymphatic filariasis.

    A manual for clinicians (Vector Control Research Centre, Misc. publication) 1997, 21:1-25.

44. Casley-Smith JR, Jamal S, Casley-Smith R: Reduction of filaritic lymphoedema and elephantiasis by 5, 6-benzo-alpha-pyrone (coumarin), and the effects of Diethylcarbamazine (DEC).

    Ann Trop Med & Parasitol 1993, 87:247-258. PubMed Abstract

45. Casley-Smith JR, Wang CT, Zi-hai Cui: Treatment of filarial lymphoedema and elephantiasis with 5, 6-benzo-alpha-pyrone (coumarin).

    BMJ 1993, 307:1037-1041. PubMed Abstract

46. World Health Organization: "Coumarin (Lodema).".

    WHO Pharmaceutical Newsletter 1996, 10:2.

47. Partono F: Filariasis in Indonesia. Clinical manifestations and basic concepts of treatment and control.

    Trans R Soc Trop Med Hyg 1984, 75:9-12. PubMed Abstract

48. Pani SP, Krishnamoorthy K, Prathibha J, Rao AS: Diethylcarbamazine and supportive measures for the treatment of Brugian filariasis.

    The National Medical Journal of India 1989, 2:260-263.

49. Freedman David D, Bui Thuy, De Almeida Fiho Paulo, Braga Cynthia, Mala e Silva Maria Carmelita, Maciel Amelia, Furtado Aadre E: Lymphoscintigraphic assessment of the effect of Diethylcarbamazine treatment on lymphatic damage in human bancroftian filariasis.

    Am J Trop Med Hyg 1995, 52:258-261. PubMed Abstract

50. Shenoy RK, Suma TK, Rajan K, Kumaraswami V: Prevention of acute adenolymphangitis in brugian filariasis: comparison of the efficacy of ivermectin and Diethylcarbamazine, each combine with local treatment of the affected limb.

    Ann Trop Med Parasitol 1998, 92:587-594. PubMed Abstract | Publisher Full Text

51. Shenoy RK, Kumaraswami V, Suma TK, Rajan K, Radhakuttyamma G: A double blind placebo-controlled study, of efficacy of oral penicillin, diethylcarbamazine, or local treatment of the affected limb in preventing acute adenolymphangitis in lymphoedema caused by brugian filariasis:.

    Ann Trop Med Parasitol 1999, 93:367-377. PubMed Abstract | Publisher Full Text

52. Das PK, Ramaiah KD, Vanamail P, Pani SP, Yuvraj J, Balarajan K, Bundy DAP: Placebo-controlled community trial of four cycles of single dose Diethylcarbamazine or ivermectin against Wuchereria bancrofti infection and transmission in India.

    Trans R Soc Trop Med Hyg 2001, 95:336-341. PubMed Abstract

53. Filis FA, Georgopoulis SE, Papas SC, Votteas V, Bastounis FA: Therapeutic efficacy of flavonoids in oedema following reperfusion on acutely ischaemic legs.

    Int Angiol 1999, 18:327-30. PubMed Abstract

54. Godeberge P: Daflon 500 mg in the treatment of hemorrhoidal disease: a demonstrated efficacy in comparison with placebo.

    Angiology 1994, 45:574-578. PubMed Abstract

55. Olszewski WL: Treatment and complications of lymphoedema.

    Atlas of the lymphatics of the lower limbs 2000, 67-94.

56. Directorate of National Malaria Eradication Programme: National Filariasis Control Programme India.

    Operational Manual 1995, 1-127.